Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma
- 82 Downloads
The combination of the antiangiogenic antibody bevacizumab with standard chemotherapy has improved the prognosis in patients with metastastic colorectal cancer and other advanced cancers. The role of combined anti-VEGF and chemotherapy in metastastic melanoma is just starting to be elucidated.
We tested this notion in three patients with advanced and therapy-refractory melanoma.
Interestingly, two patients achieved objective regressions after three courses of therapy; the third patient, albeit progressing demonstrated a pronounced liquid necrosis in bulky lymphnode metastasis.
Further studies are warranted to scrutinise these impressive therapeutic effects on the combination of bevacizumab and chemotherapy in melanoma.
KeywordsMelanoma Metastases Therapy Angiogenesis Chemotherapy
- Demirkesen C, Buyukpinarbasili H, Ramazanoglu R, Oguz O, Mandel NM, Kaner G (2006) The correlation of angiogenesis with metastasis in primary cutaneous melanoma: a comparative analysis of microvessel density, expression of vascular endothelial growth factor and basic fibroblast growth factor. Pathology 38:132–137PubMedCrossRefGoogle Scholar
- Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluororuracil, and leucovorin for metastastic colorectal cancer. N Engl J Med 350:2335–2342PubMedCrossRefGoogle Scholar